
usd feb pm et
summari compani develop provid research product servic analysi
genet variat function
price-to-earnings oper ep
risk assess reflect high depend
rapid technolog advanc maintain market
share also see risk materi amount
order custom depend
govern fund research initi
frequent risk reduct amid polit budget
negoti risk balanc
domin market share dna sequenc industri
loyal custom profil view
grow proport consum revenu tend
recur less volatil instrument revenu
apr ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
revenu grew yoy thank
strong growth yoy core
sequenc busi total revenu
particularli sequenc consum
grew yoy post revenu
off-set declin microarray
revenu due weak
array servic yoy
relat lower demand
revenu emea total yoy
china total yoy
consider thank strong
contribut biobank sequenc
low base effect due tariff-rel
stock china major
portion revenu continu
gener america
yoy thank growth sequenc
consum vitro diagnost devic
partnership revenu offset dtc
expect total revenu
impli yoy growth yoy
thank continu strength core
sequenc busi yet expect ep
growth around forecast
maintain less oper leverag gain
sg expens contain lower
interest cost
late januari upgrad rate buy
hold lift target
ep estim close
current forward price-to-earnings
think well posit see
continu momentum driven solid
growth novaseq sequenc
achiev view continu
global market leader next
gener sequenc market share
justifi premium valuat peer
expect similar growth major
sequenc busi offset
potenti declin microarray
revenu case weak seen
dtc segment persist
coronaviru outbreak offer
opportun threat main
posit increas demand
consum sequenc use
identifi genom profil viru yet
patient avoid go hospit
prenat cancer test china might
neg impact risk see
slowdown novaseq shipment growth
signific cut govern fund
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
senior vice presid
global qualiti
corpor overview develop research tool large-scal analysi genet variat
function account physic differ among human eye color height
genet variat also import medic consequ includ predisposit diseas
differenti respons drug tool assist research autom billion test necessari
collect raw genet data imbed dna sequenc contain everi live cell
scientist use data investig dna sequenc dictat biolog event molecular
scale develop inform medic valuabl applic field studi known
genom rapidli expand given potenti custom diagnos treatment
improv drug therapi cure diseas
corpor strategi import aspect ilmn busi understand relationship
dna sequenc machin instrument consum instrument perman fixtur
laboratori larg up-front cost ilmn power dna sequenc machin novaseq
releas januari cost roughli million per unit convers consum
lower-cost prepar kit scientist arrang test sampl feed machin
run dna sequenc test product relationship somewhat analog razor razor blade
model lab typic purchas small number instrument continu order larg
volum consum life machin run thousand sequenc test way
singl instrument sale lead durabl long-term sale consum
last decad ilmn annual sale growth follow cyclic trend relat new instrument
launch five-quart stretch year-over-year sale growth averag coincid launch
hiseq sequenc machin hiseq launch produc five
quarter growth averag new instrument ramp though growth tend
slower expans ilmn instal base instrument field new product launch
actual reduc cyclic howev higher baselin recur consum servic demand
establish ilmn contribut sale instrument fallen
view trend favor consum carri higher margin addit lower
januari introduc novaseq system line think could reduc cost
sequenc human genom within year note year-over-year
instrument sale fell posit growth neg june quarter howev event
typic occur near peak total sale growth expect ilmn cyclic slowdown less sever
novaseq product cycl howev due larger sale mix consum versu
market profil signific custom concentr tool servic use
wide varieti research govern univers lab well commerci pharmaceut
biotechnolog agrigenom diagnost lab around world custom increas
util ilmn tool servic genom field rapidli develop materi
geograph composit year-over-year growth respect ilmn total sale unit state
total growth europ middl east africa total growth china
sequenc technolog continu advanc cost sequenc singl genom entir set
dna data contain cell continu fall accord nation institut cost
sequenc genom took sever week versu around sever
hour reduc time cost allow increas number entrant appli
genom market accord cb insight juli global fund genom startup
alreadi surpass record set pace doubl full-year
expect particip increasingli util sequenc tool servic effort develop
clinic commerci genom applic
competit landscap competit landscap intens sever larger
diversifi publicly-trad compani industri well numer emerg privat compani
publicly-trad compani includ thermo fisher scientif acquir main competitor life
technolog februari agil
undisput leader next gener sequenc system market share estim
compani sizabl instal base system like ilmn hold competit
advantag emerg compani view instal system drive persist
sale consum product util consist invest innov also
next-gen sequenc custom tend sticki transit one system anoth costli
time-consum given requir train new system integr natur sequenc
instrument laboratori work flow
financi trend sale increas compound annual growth
rate compound-annual-growth-rate mark sharp slowdown compound-annual-growth-rate three-year period
adjust pre-tax incom per share increas compound-annual-growth-rate
conserv capit view net debt debt less cash equival
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
fairli valu
neutral sinc januari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
neutral fundament outlook
lst sub-industri
next year expect earn growth
remain posit slow sharpli
rate achiev posit
earn growth view
healthi fund public medic research
demand growth emerg market expect
factor balanc slower
biopharmaceut spend growth
neg effect trade tariff
budget nation institut
nih grow rapidli
academ govern lab turn
help drive sale growth mani lst
compani suppli lab nih
fy sep budget grew vs prior
year follow growth
fy fy respect mark
major acceler averag growth
fy fy believ
boost sale lst
sub-industri grew
expect lst firm
continu see strong demand
publicly-fund lab
prolifer advanc health care around
world also continu drive demand
growth lst firm trend
remain particularli strong china
emerg market rapidli grow middl
class gain access advanc health
care drive suppli need new expand
medic research lab facil
estim trend drove growth
lst sub-industri sale
asia-pacif region expect
continu posit long-term driver
contrast strong demand growth
expect publicly-fund client think
biopharmaceut firm moder
 spend growth year ahead
estim total
spend
biopharmaceut compani grew
annual averag expect slow
howev
mani biopharmaceut firm look limit
spend growth off-set recent
revenu headwind patent expir
public scrutini high drug price larg
swath biopharma typic flow
lst firm suppli depart
research tool softwar contract servic
accordingli think slowdown
biopharma growth reduc tailwind
mani lst firm receiv
client group recent year
final recent escal trade tariff
neg impact lst earn
growth view expect
continu analyt
instrument maker lst sub-industri
global suppli chain see
strong oper profit growth
first half brought lower profit
mani busi think shift
relat escal tariff impos
 -china trade
soften demand -made
instrument china rais product
cost instrument maker limit
suppli chain flexibl end sight
current trade disput expect tariff
continu pressur sale growth
oper margin sub-industri
year-to-d septemb
 life scienc tool
servic rose broader
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra maintain hold opinion share inc
keep price target ep estim --
histor forward price-to-earnings averag due slow growth lower
ep estim today announc
preliminari revenu repres yoy growth fell well short
consensu estim growth full-year revenu growth
guidanc also lower sent share
approxim around mid-day expect growth expect
come compet dna sequenc firm improv
technolog recent mark two-year anniversari latest
major system upgrad histor driven cyclic revenu
long-term outlook leader rapidli grow dna sequenc
field remain strong continu neutral share due caution
forward price-to-earnings valuat peer averag /colin scarola
pm et cfra maintain hold opinion share inc
rais target ep estim
 histor forward price-to-earnings averag due slow growth
increas ep estim
ep vs beat consensu sale grew yoy
continu deceler recent peak quarterli sale growth
yoy declin instrument sale revenu hurt
growth consum growth yoy saw slowest pace sinc
also note materi drop adjust pre-tax margin
led flat adjust pre-tax incom yoy
despit revenu growth think rise competit dna sequenc
product contribut growth slowdown lower margin
attract growth prospect view maintain lead
burgeon sequenc market remain neutral due caution
premium valuat peer /colin scarola
analyst research note compani news
et cfra rais opinion inc buy hold
lift target higher price-to-earnings
ep estim close current ntm forward price-to-earnings reflect
view share gain potenti see continu momentum trim
ep stay line high-end
ilmn ep guidanc rang maintain ep
estim ep vs higher consensu
view revenu grew yoy thank strong growth yoy sequenc
total revenu particularli sequenc consum grew
yoy post revenu provid revenu growth
guidanc achiev view continu global
market leader next gener sequenc market share
expect similar growth major sequenc busi offset
potenti declin microarray revenu weak seen
dtc segment persist /sel hardi
et cfra maintain hold opinion share inc
rais target ep estim
histor forward price-to-earnings averag rais
ep maintain ep estim
lift target price reflect posit momentum follow senior
manag share expect solid growth novaseq
sequenc consum last
month see potenti addit appreci limit lengthi
regulatori approv process caus termin
acquisit pacbio yesterday although deal would solidifi
ilmn market posit elimin small competitor view
cancel major impact global market leader
next gener sequenc market share yet prefer
remain neutral ntm price-to-earnings multipl look expens view
pm et cfra maintain hold opinion share inc
keep target ep estim --
histor forward price-to-earnings averag due slow growth lift
ep estim maintain start ep
vs beat consensu share roughli
today despit ep guidanc significantli rais view
rise profit main focu mani investor
like disappoint increas revenu guidanc
expect top line expect come peer improv sequenc
technolog thru ytd sale yoy put track
slowest year sale growth sinc instrument sale
total main laggard ytd nearli three year
elaps without major instrument upgrad cycl novaseq launch
consum servic continu grow though
et cfra maintain hold opinion share inc
keep target price ep estim --
histor forward price-to-earnings averag due slow growth lower
ep estim revenu
grew yoy slowest quarter growth sinc growth
slow full-year yoy clip
surpris given histori lead technolog race
rapidli grow genom field wide miss consensu estim sale
growth slow sale growth led yoy drop adjust oper
incom consecut quarter declin expect growth
expect come compet dna sequenc firm improv
technolog although long-term outlook leader
rapidli grow dna sequenc field remain strong continu neutral
share howev due caution larg valuat premium
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
